Onxeo Reaches Second Milestone Of BPIFrance Grant Dedicated To Livatag® Development As Part Of National Institute for Clinical Excellence (NICE) Consortium

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, today announces the second payment of €1.25 million from BPIFrance (ex OSEO) as a part of the funding granted to support the NICE (Nano Innovation for Cancer) consortium.

Help employers find you! Check out all the jobs and post your resume.